Phase I trial of radiation therapy and sorafenib in unresectable liver metastases

Radiotherapy and Oncology

Volumn 123, Issue 2, 2017, Pages 234-239

  Goody, Rebecca B ^a   Brade, Anthony M ^a   Wang, Lisa ^b   Craig, Tim ^b   Brierley, James ^a   Dinniwell, Robert ^a   Wong, Rebecca K S ^a   Cho, Charles ^a,c   Kim, John ^a   Kassam, Zahra ^a,c   Ringash, Jolie ^a   Knox, Jennifer J ^b   Dawson, Laura A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Stronach Regional Cancer Centre   (Canada)

Author keywords

Liver metastases; Radiotherapy; Sorafenib

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DYSPEPSIA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOFRACTIONATED RADIOTHERAPY; HYPONATREMIA; HYPOPHOSPHATEMIA; LIVER FAILURE; LIVER METASTASIS; LIVER WEIGHT; MALE; MAXIMUM TOLERATED DOSE; MUSCULOSKELETAL DISEASE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RADIATION DOSE; RADIATION INJURY; SKIN MANIFESTATION; SKIN TOXICITY; STEREOTACTIC BODY RADIATION THERAPY; THORAX PAIN; THROMBOCYTOPENIA; WHOLE LIVER RADIOTHERAPY; ANALOGS AND DERIVATIVES; CHEMORADIOTHERAPY; CLINICAL TRIAL; LIVER; LIVER TUMOR; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; RADIATION RESPONSE; RADIOSURGERY; SECONDARY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROSPECTIVE STUDIES; RADIOSURGERY;

EID: 85012008735     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2017.01.018     Document Type: Article

References (36)

1. Jemal, A., Murray, T., Samuels, A., et al. Cancer statistics, 2003. CA Cancer J Clin 53 (2003), 5–26.
2. McLoughlin, J.M., Jensen, E.H., Malafa, M., Resection of colorectal liver metastases: current perspectives. Cancer Control 13:1 (2006), 32–41.
3. Zdenkowski, N., Chen, S., Van der Westhuizen, A., Ackland, S., Curative strategies for liver metastases from colorectal cancer: a review. The Oncologist 17 (2012), 201–211.
4. Reddy, S.K., Barbas, A.S., Marroquin, C.E., et al. Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis. J Am Coll Surg 204 (2007), 372–382.
5. Elias, D., Cavalcanti de Albuquerque, A., Eggenspieler, P., et al. Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg 187 (1998), 487–493.
6. Kavanagh, B.D., Schefter, T.E., Cardenes, H.R., et al. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol 45 (2006), 848–855.
7. Dawson, L.A., Normolle, D., Balter, J.M., et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 53 (2002), 810–821.
8. Schefter, T.E., Kavanagh, B.D., Timmerman, R.D., et al. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 62 (2005), 1371–1378.
9. Pan, C.C., Kavanagh, B.D., Dawson, L.A., et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 76 (2010), S94–100.
10. McGinn, C.J., Ten Haken, R.K., Ensminger, W.D., et al. Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model. J Clin Oncol 16 (1998), 2246–2252.
11. Lee, M.T., Kim, J.J., Dinniwell, R., et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27 (2009), 1585–1591.
12. Dawson, L.A., Eccles, C., Craig, T., Individualized image guided iso-NTCP based liver cancer SBRT. Acta Oncol 45 (2006), 856–864.
13. Dawson, L.A., Ten Haken, R.K., Partial volume tolerance of the liver to radiation. Semin Radiat Oncol 15 (2005), 279–283.
14. Llovet, J.M., Ricci, S., Mazzaferro, V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008), 378–390.
15. Lee, C.G., Heijn, M., di Tomaso, E., et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60 (2000), 5565–5570.
16. Hess, C., Vuong, V., Hegyi, I., et al. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer 85 (2001), 2010–2016.
17. Abdollahi, A., Griggs, D.W., Zieher, H., et al. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 11 (2005), 6270–6279.
18. Abdollahi, A., Lipson, K.E., Han, X., et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 63 (2003), 3755–3763.
19. Bischof, M., Abdollahi, A., Gong, P., et al. Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. Int J Radiat Oncol Biol Phys 60 (2004), 1220–1232.
20. Huber, P.E., Bischof, M., Jenne, J., et al. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 65 (2005), 3643–3655.
21. Mauceri, H.J., Hanna, N.N., Beckett, M.A., et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394 (1998), 287–291.
22. Schueneman, A.J., Himmelfarb, E., Geng, L., et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63 (2003), 4009–4016.
23. Kuo, Y.C., Lin, W.C., Chiang, I.T., et al. Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-kappaB expression in vitro and in vivo. Biomed Pharmacother 66 (2012), 12–20.
24. Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
25. Cheng, A.L., Kang, Y.K., Chen, Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10 (2009), 25–34.
26. Brandi, G., De Lorenzo, S., Di Girolamo, S., et al. Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib. Tumori 101 (2015), e46–48.
27. Van Hootegem, A., Verslype, C., Van Steenbergen, W., Sorafenib-induced liver failure: a case report and review of the literature. Case Reports Hepatol, 2011, 2011, 941395.
28. Rao, J., Feng, M., Qian, X., et al. Liver transplantation treating the patient with hepatic failure associated with sorafenib treatment: report of a case. Hepatogastroenterology 60 (2013), 1317–1319.
29. Gupta-Abramson, V., Troxel, A.B., Nellore, A., et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26 (2008), 4714–4719.
30. Ricke, J., Bulla, K., Kolligs, F., et al. Safety and toxicity of radioembolization plus sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC. Liver Int 35 (2015), 620–626.
31. Ogasawara, S., Kanai, F., Obi, S., et al. Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. Hepatol Int 5 (2011), 850–856.
32. Brade, A.M., Ng, S., Brierley, J., et al. Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 94 (2016), 580–587.
33. Borgelt, B.B., Gelber, R., Brady, L.W., et al. The palliation of hepatic metastases: results of the Radiation Therapy Oncology Group pilot study. Int J Radiat Oncol Biol Phys 7 (1981), 587–591.
34. Yin, H., Lu, K., Qiao, W.B., et al. Whole-liver radiotherapy concurrent with chemotherapy as a palliative treatment for colorectal patients with massive and multiple liver metastases: a retrospective study. Asian Pac J Cancer Prev 15 (2014), 1597–1602.
35. Yeo, S.G., Kim, D.Y., Kim, T.H., et al. Whole-liver radiotherapy for end-stage colorectal cancer patients with massive liver metastases and advanced hepatic dysfunction. Radiat Oncol, 5, 2010, 97.
36. Shilkrut, M., Sapir, E., Hanasoge, S., et al. Phase I trial of dose-escalated whole liver irradiation with hepatic arterial fluorodeoxyuridine/leucovorin and streptozotocin followed by fluorodeoxyuridine/leucovorin and chemoembolization for patients with neuroendocrine hepatic metastases. Am J Clin Oncol, 2016, 10.1097/COC.0000000000000276.